Calcium Channel Blockers Market Predicted to Reach $24 Billion by 2031, Propelled by 5.7% CAGR – TMR Study

Increase in the prevalence of cardiovascular diseases, a surge in geriatric population, and rise in the availability of combination therapies are driving the global calcium channel blockers market. Increase in adoption of combination therapies and development of newer formulations of CCBs with improved pharmacokinetic properties and fewer side effects offer lucrative opportunities to market players.

 | Source: Transparency Market Research Transparency Market Research

Wilmington, Delaware, United States, May 29, 2023 (GLOBE NEWSWIRE) -- The global calcium channel blockers (CCB) market is forecast to be valued at US$ 24 billion, expected to incline at a value CAGR of 5.7% from 2023 to 2031. As of 2023, a valuation of US$ 15.3 billion is anticipated for the market. The increasing prevalence of cardiovascular conditions is one primary driver expected to propel sales in the future.

Calcium channel blockers (CCBs) help inhibit the entry of calcium ions into the smooth muscle cells of blood vessels. Therefore, blood vessels relax and dilate, helping improve blood flow and reducing risks of heart attacks. CCBs additionally help improve the flow of oxygen to the heart, thus promoting good heart health.

Unlock Insights: Download a Sample PDF Copy of this Research Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=35687

Cardiovascular diseases today rank among the leading cause of fatalities across the world. The World Health Organization (W.H.O) estimates that 17.9 million people succumbed to cardiovascular diseases in 2019. This represents 32% of all global deaths. Considering this high fatality number, governments worldwide are making it a top priority to detect early signs of the disease and manage the same through several approaches. One such approach is to use calcium channel blockers.

For treating CVDs, healthcare practitioners are reliant on combination therapies. This has improved positive patient outcomes. Several clinical trials are testimony to this fact. The ACCOMPLISH trial, for instance, discovered a combination therapy via the use of amlodipine, a CCB and benazepril, an ACE inhibitor. The administration of both drugs in combination yielded positive results compared to their usage in isolation.

Likewise, the ALLHAT trial found that a combination of amlodipine and ACE inhibitor Lisinopril proved to be more effective in reducing the risk of heart failure than the diuretic drug chlorthalidone.

Key Takeaways from the Report

  • As of 2022, the calcium channel blockers market was valued at US$ 14.5 billion
  • From 2023 to 2031, the market for calcium channel blockers is likely to expand by 1.5x
  • By application, hypertension treatment is expected to provide maximum opportunities for calcium channel blockers manufacturers
  • Treatment through phenylalykamines is expected to gain traction in the coming decade
  • Online pharmacies are likely to emerge as the most preferred distribution channels for availing calcium channel blockers

Your Research, Your Way: Customized Solutions at Your Fingertips - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=35687

Calcium Channel Blockers: Primary Growth Drivers

  • The demand for calcium channel blocker medicines is inclining because of a shift toward combination therapies for cardiovascular disorders
  • With an increased demand for generic medications such as amlodipine, nifedipine, and diltiazem, the demand for CCB drugs is expected to rise
  • Retail pharmacies in several countries are assisting in making CCB drugs available to a wider range of customers. This initiative is expected to propel sales to a large extent

Calcium Channel Blockers Market: Regional Landscape

  • North America is expected to be the frontrunner with respect to calcium channel blocker drugs consumption. Growth is attributed to a high prevalence of hypertension among citizens
  • Asia Pacific is another lucrative market for calcium channel blockers, given the unceasing initiatives by healthcare providers to eradicate chronic health issues such as cardiovascular disorders

Calcium Channel Blockers Market: Competitive Landscape

The global market for calcium channel blockers is characterized by the presence of a significant number of market players. This renders the market highly competitive. Prominent players profiled in Transparency Market Research’s report include:

  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Company, Inc.
  • Novartis AG
  • AstraZeneca
  • Merck & Co. Inc.
  • GSK plc
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Daiichi Sankyo Company, Limited

Some recent developments in the calcium channel blockers landscape are as follows:

  • On February 24, 2022, CMP Pharma received FDA approval for its Norliqva (Amlodipine) Oral Solution. This oral liquid solution, with a concentration of 1mg/mL, is the first and only FDA-approved medication of its kind that contains the besylate salt of amlodipine, a long-acting calcium channel blocker that is commonly used to manage hypertension and angina.
  • On May 17, 2021, Milestone Pharmaceuticals, Inc. entered into an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and potentially commercialize an investigational drug Etripamil in Greater China for the treatment of paroxysmal supraventricular tachycardia (PSVT) and other cardiovascular conditions. Milestone Pharmaceuticals is focused on developing innovative cardiovascular medicines, and the partnership with Ji Xing Pharmaceuticals will allow them to expand the potential reach of Etripamil in Greater China, if approved.

Elevate Your Business Strategy. Buy this Premium Research Report for Immediate Delivery: https://www.transparencymarketresearch.com/checkout.php?rep_id=35687&ltype=S

Market Segmentation

Drug Class

  • Phenylalkylamine
  • Benzothizepine
  • Dihydropyridine
    • 1st Generation
    • 2nd Generation
    • 3rd Generation

Application

  • Hypertension
  • Angina
  • Arrhythmia
  • Hypertrophic Cardiomyopathy
  • Others (Raynaud's disease, etc.)

Route of Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com


Mot-clé

Calcium Channel Blockers Phenylalkylamine Benzothizepine Dihydropyridine Arrhythmia